A randomized phase II study of pivanex and docetaxel compared to docetaxel monotherapy in patients with previously treated advanced NSCLC

被引：1
|
作者：
Raghunadharao, D
Koralewski, P
Serwatowski, P
Gruszfeld, A
Lakshmaiah, K
Szczesna, A
Savin, M
Yen, K
Bhatnagar, A
Green, M
机构：
[1] Nizams Inst Med Sci, Hyderabad, Andhra Pradesh, India
[2] Szpital Specjalistyczny Rydygiera, Krakow, Poland
[3] Szpital Specjalistyczny Alfreda, Szczecin, Poland
[4] Warminsko Mazurskie Ctr Onkol, Olsztyn, Poland
[5] Kidwai Mem Inst Oncol, Bangalore, Karnataka, India
[6] Mazawieckie Ctr Leczenia, Otwock, Poland
[7] Texas Canc Ctr Med City, Dallas, TX USA
[8] Tita Pharmaceut Inc, San Francisco, CA USA
[9] Med Univ S Carolina, Charleston, SC 29425 USA
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)81053-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S265 / S265
页数：1
相关论文
共 50 条
  • [1] Adverse events in NSCLC patients treated with docetaxel monotherapy
    Liu, Yangyang
    Tyczynski, Jerzy E.
    Zhang, Dongmu
    Choi, Christy
    Wolff, Johannes
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 136 - 136
  • [2] A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma
    Frederick Locke
    Joseph I. Clark
    Thomas F. Gajewski
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 509 - 514
  • [3] Sequential docetaxel and vinorelbine for patients with advanced breast cancer previously treated with anthracyclines: A phase II study
    Brugnatelli, S
    Riccardi, A
    Danova, M
    Pugliese, P
    Tinelli, C
    Luchena, G
    Bernardo, A
    Giardina, G
    Fava, S
    Montanari, G
    Pedrotti, C
    Poli, AM
    ONCOLOGY REPORTS, 2001, 8 (04) : 801 - 805
  • [4] A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma
    Locke, Frederick
    Clark, Joseph I.
    Gajewski, Thomas F.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (03) : 509 - 514
  • [5] Bortezomib ± docetaxel in previously treated patients with advanced nonsmall cell lung cancer (NSCLC):: A phase 2 study.
    Fanucchi, MP
    Fossella, F
    Fidias, P
    Natale, RB
    Belt, RJ
    Carbone, DP
    Govindan, R
    Raez, L
    Robert, F
    Schiller, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 629S - 629S
  • [6] Presentation of a Flims study: Randomized phase II study of docetaxel/oxaliplatin and docetaxel in previously treated non-small cell lung cancer patients
    Belvedere, O.
    Follador, A.
    Gaiardo, M.
    Grossi, F.
    Rossetto, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 54 - 54
  • [7] Phase II study of docetaxel monotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC)
    Takigawa, N
    Segawa, Y
    Kishino, D
    Fujiwara, K
    Shinkai, T
    Watanabe, Y
    Tabata, M
    Kiura, K
    Ueoka, H
    Tanimoto, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 776S - 776S
  • [8] A Phase II Trial of Docetaxel and Vinorelbine in Patients with Advanced Breast Cancer Previously Treated with Anthracyclines
    Vici, Patrizia
    Di Lauro, Luigi
    Sergi, Domenico
    Foggi, Paolo
    Viola, Giuditta
    Mottolese, Marcella
    Giotta, Francesco
    Fattoruso, Silvia I. S.
    Corsetti, Serena
    Giannarelli, Diana
    Botti, Claudio
    Lopez, Massimo
    ONCOLOGY, 2008, 75 (3-4) : 175 - 181
  • [9] HEALTHCARE RESOURCE UTILIZATION IN PATIENTS RECEIVING PEMBROLIZUMAB OR DOCETAXEL WITH PREVIOUSLY TREATED ADVANCED NSCLC
    Huang, M.
    Pellissier, J.
    Liao, J.
    VALUE IN HEALTH, 2016, 19 (07) : A755 - A755
  • [10] Phase II study of oxaliplatin, docetaxel, and sargramostim (GM-CSF) in patients with previously treated advanced melanoma
    Locke, F. L.
    Clark, J. I.
    Gajewski, T. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345